Arix Bioscience PLC

Receive alerts
Market Cap:
£150.06 m
52 weeks high
52 weeks low

Viewing results 1-25 of 54

Retail & consumer

Immuno-oncology: All you wanted to know but were too afraid to ask

Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers...

on 05/27/2019

Arix Biosciences - venture capital firm flies under the market's radar

Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves...

on 05/07/2019

Arix Bioscience portfolio company Autolus Therapeutics raises US$109mln

The total of US$109mln is more than Autolus had originally set out to raise from the market...

on 04/16/2019

Arix Bioscience to invest another US$5mln in Autolus

Autolus said earlier this week it was looking to raise money from investors, and it has today confirmed plans to raise US$100.8mln through the issue of 4.2mln shares at US$24 each...

on 04/11/2019

Arix Bioscience confirms Autolus to launch proposed public offering

The final price has not yet been set but Autolus is planning on issuing up to 4.6mln American Depositary Shares (ADS) as part of the offering...

on 04/09/2019

Arix Bioscience increases stake in cutting-edge cancer company after backing its latest financing round

The venture capital company committed £3.4mln to Aura Biosciences' Series D financing round ...

on 04/02/2019

Autolus Therapeutics presents promising leukemia trial data at American Association for Cancer Research's annual meeting

After one month, eight of the nine patients who could be evaluated in the study reported a molecular complete response or no evidence of cancer via CT or PET imaging...

on 04/01/2019

Arix Bioscience upbeat on prospects after making "encouraging progress" last year

The net asset value, which is closely monitored by the market, was £270mln, or £2 a share, a rise of 48p from a year ago. The stock closed Wednesday at 144p...

on 03/28/2019

Arix Bioscience’s portfolio company Autolus announces positive safety data for AUTO3 ahead of inaugural R&D day

Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease negative complete responses...

on 03/26/2019

Arix Bioscience invests US$15mln in sickle cell treatment developer Imara

The health and life science investor said the sum would give it a 10% stake in the company and expand the breadth of its portfolio...

on 03/18/2019

Arix Bioscience appoints Joe Anderson CEO in boardroom reshuffle

Executive chairman Jonathan Peacock will stay in role, but in a non-executive capacity ...

on 02/19/2019

Arix Bioscience quids in after Harpoon completes flotation on NASDAQ

Harpoon is well-positioned to play a significant role in immuno-oncology, Arix said...

on 02/14/2019

Arix Bioscience boost after Harpoon NASDAQ float

The fair value of the company's investment in Harpoon has grown by £6.2mln ...

on 02/08/2019

Arix Bioscience says Harpoon Therapeutics’ IPO pricing range would hike holding value by £4.2mln-£7.9mln

The global healthcare and life science company supporting medical innovation said that increase was compared to the current £20.2mln value of its holding in Harpoon...

on 01/29/2019

Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

Harpoon Therapeutics has filed a registration statement with the US Securities and Exchange Commission relating to a proposed underwritten initial public offering...

on 12/28/2018

Arix Bioscience sees multiple advancements across portfolio

Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq...

on 12/03/2018

Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy

PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin...

on 12/03/2018

Arix Biosciences hails phase I success of investee company Pharmaxis

Arix is a cornerstone investor in the ASX life sciences group...

on 11/15/2018

Arix Bioscience participates in US$70mln Harpoon Series C investment round

Including the £6.1mln Series C investment, the value of Arix’s 11.3% stake in Harpoon has increased to £20.2mln...

on 11/12/2018

Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial

The data from a phase Ib/II trial of Aura’s AU-011 eye cancer treatment show the injection doesn’t do too much damage to the surrounding healthy tissue in patients’ eyes...

on 10/30/2018

Arix Biosciences boost after investee company floats on NASDAQ

The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio...

on 10/24/2018

Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq

As a result of the IPO, the value of Arix’s stake in LogicBio has soared to almost £23mln, including the extra investment announced today...

on 10/19/2018